Myriad Genetics, Inc. (NASDAQ:MYGN) CFO Richard Bryan Riggsbee sold 25,000 shares of Myriad Genetics stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $41.50, for a total transaction of $1,037,500.00. Following the completion of the sale, the chief financial officer now owns 120,566 shares of the company’s stock, valued at $5,003,489. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:MYGN opened at $47.08 on Monday. Myriad Genetics, Inc. has a 12 month low of $22.07 and a 12 month high of $50.44. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 3.67 and a beta of 0.81. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.86 and a current ratio of 3.15. The company has a 50 day moving average price of $27.20.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.34 EPS for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.04). Myriad Genetics had a net margin of 2.62% and a return on equity of 9.82%. The firm had revenue of $216.60 million during the quarter, compared to the consensus estimate of $217.76 million. During the same period in the prior year, the business earned $0.34 EPS. The company’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, research analysts expect that Myriad Genetics, Inc. will post 1.44 EPS for the current fiscal year.
A number of research firms have issued reports on MYGN. Barclays upgraded shares of Myriad Genetics from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $18.00 to $40.00 in a research note on Thursday. Zacks Investment Research upgraded shares of Myriad Genetics from a “sell” rating to a “hold” rating and set a $30.00 target price for the company in a research note on Monday, July 1st. ValuEngine upgraded shares of Myriad Genetics from a “sell” rating to a “hold” rating in a research note on Thursday. Bank of America upgraded shares of Myriad Genetics from an “underperform” rating to a “neutral” rating in a research note on Friday. Finally, Cowen cut shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and set a $26.64 target price for the company. in a research note on Tuesday, July 9th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $39.74.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Read More: Rule of 72
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.